Autolus Therapeutics Ltd (AUTL) ADS Each Rep 1 Ord Shs

Sell:$1.51Buy:$1.52$0.06 (3.50%)

NASDAQ:1.18%
Market closed |
Prices delayed by at least 15 minutes
Sell:$1.51
Buy:$1.52
Change:$0.06 (3.50%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$1.51
Buy:$1.52
Change:$0.06 (3.50%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Key people

Michael W. Bonney
Chairman of the Board
Christian Martin Itin
Chief Executive Officer, Executive Director
Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Robert Dolski
Chief Financial Officer, Senior Vice President
Christopher Vann
Chief Operating Officer, Senior Vice President
Edgar Braendle
Senior Vice President
David Brochu
Senior Vice President, Chief Technical Officer
Brent Rice
Senior Vice President, Chief Commercial Officer
Matthias Will
Chief Development Officer
Robert W. Azelby
Director
Elisabeth Leiderman
Director
Ravi M. Rao
Director
Linda C. Bain
Non-Executive Independent Director
John Edward Berriman
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    AUTL
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US05280R1005
  • Market cap
    $428.49m
  • Employees
    647
  • Shares in issue
    266.14m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.